You are here

breast cancer

AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment

AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment

BioSpace

Flag link:

FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer

FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer

Pharm Exec

Flag link:

Olema scores in Phase II breast cancer trial with Phase III dosing in weeks

Olema scores in Phase II breast cancer trial with Phase III dosing in weeks

Clinical Trials Arena

clinical tirals

Flag link:

Seagen wins future royalties in Enhertu patent dispute

Seagen wins future royalties in Enhertu patent dispute

Pharmaphorum

Flag link:

BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC

BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC

Fierce Biotech

antibody-drug conjugate

Flag link:

Daiichi Sankyo reports positive results from trial of breast cancer therapy

Daiichi Sankyo reports positive results from trial of breast cancer therapy

Clinical Trials Arena

clinical trials

Flag link:

AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead

AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead

BioSpace

antibody-drug conjugate

clinical trials

Flag link:

Seagen’s breast cancer therapy meets main goal in late-stage study

Seagen’s breast cancer therapy meets main goal in late-stage study

Medical Marketing and Media

clinical trials

Flag link:

Merck's Keytruda meets main goal in late-stage breast cancer study

Merck's Keytruda meets main goal in late-stage breast cancer study

Reuters

clinical trials

Flag link:

ASCO in Review: Oncologists See Practice-Changing, Affirming Data

ASCO in Review: Oncologists See Practice-Changing, Affirming Data

BioSpace

non-small cell lung cancer

Moderna Therapeutics

Flag link:

Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment

Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment

BioSpace

Burning Rock Biotech

genomic profiling

OncoScreen Plus

Flag link:

Novartis drug helps stop breast cancer’s return in large study

Novartis drug helps stop breast cancer’s return in large study

BioPharma Dive

clinical trials

Flag link:

Byondis' breast cancer drug fails to bloom as FDA denies approval

Byondis' breast cancer drug fails to bloom as FDA denies approval

Fierce Biotech

antibody-drug conjugate

HER-2 positive breast cancer

Flag link:

Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect

Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect

Fierce Biotech

brain metastases

Flag link:

Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec

Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec

Fierce Pharma

Flag link:

OncoRix's breast cancer integrative solution demonstrated enhanced efficacy when combined with chemotherapy in an ex-vivo model

OncoRix's breast cancer integrative solution demonstrated enhanced efficacy when combined with chemotherapy in an ex-vivo model

BioSpace

Flag link:

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

BioSpace

clinical trials

Flag link:

Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline

Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline

Endpoints

Flag link:

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

Fierce Pharma

Flag link:

Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924

Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924

NASDAQ

Aileron Therapeutics

clinical trials

Flag link:

Pages